Compare Gilead Sciences, Inc. (GILD) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Gilead Sciences, Inc. trades at $138.44 (market cap $168.47B), while Schwab US Large Cap Growth ETF trades at $35.93. The key difference: Gilead Sciences, Inc. pays a 2.41% dividend while Schwab US Large Cap Growth ETF pays none, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | SCHG | |
|---|---|---|
Market Cap | $168.47B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $35.94 |
52-Week Low | $110.56 | $28.10 |
Enterprise Value | $191.54B | — |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $138.14, up 1.75% in the last session, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q2 2026 revenue growth of 8% year-over-year, driven by HIV drug sales, though a net loss of $6.75 per share resulted from acquisition-related charges. Analyst consensus is strongly bullish with a $151.22 price target, while institutional activity shows mixed positioning adjustments.
The outlook for GILD is positive due to robust HIV franchise performance and raised 2026 guidance, but risks include patent cliffs by the mid-2030s and integration costs from acquisitions. The stock offers potential upside from pipeline advancements, though volatility may persist from earnings fluctuations and competitive pressures.
SCHG trades at $35.61, showing minimal daily movement (-0.11%) amid a bullish technical outlook with strong moving average signals. The ETF's concentrated portfolio in large-cap growth stocks, particularly technology leaders, drives performance but introduces concentration risk. Recent news highlights SCHG's strong historical returns and low 0.04% expense ratio as key advantages for long-term investors.
The outlook remains positive given SCHG's exposure to AI and technology growth trends, though elevated RSI levels suggest potential near-term consolidation. Risks include heavy reliance on top holdings and sensitivity to interest rate changes. Analyst sentiment is generally favorable for long-term growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
